ArticleNews reportPHN-06362026-11-04 01:30 CT

Eli Lilly Just Gained 22% in a Month: Take Profits, or Buy More?

Source · TIKR.com

TLDR

TIKR reports that Eli Lilly shares gained 22% in the month through October 30, alongside strong earnings and higher revenue guidance. The article also reports that Lilly announced its experimental drug retatrutide outperformed Ozempic in a Phase 3 trial in adults with type 2 diabetes.

01—Key points

01According to the article, Lilly reported A1C reductions of 2.2 percentage points with retatrutide versus 1.8 with Ozempic, and weight loss of 19.5%–20.9% versus 9.4%.
02Lilly’s third-quarter revenue reportedly rose 39% to $24.4 billion, and management raised its 2026 revenue guidance to $91 billion–$92 billion.
03TIKR highlighted growing obesity-treatment demand while identifying lower realized prices and future coverage uncertainty as business risks.

Why it matters Editorial

The reported trial results and revenue growth highlight competition in diabetes and obesity treatments, while pricing pressure could affect future business performance.

Read the original at TIKR.com↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.